Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB
Phase 2 study of PVX108 to commence in United States and Australia Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins...
Mar 3, 2022
Aravax appoints Principal Investigators for PVX108 Phase 2 trials in United States and Australia
27 August 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...
Aug 26, 2021
Aravax presents PVX108 Phase 1 longitudinal immunology data at EAACI 2021.
13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...
Jul 12, 2021
Aravax appoints Financial Executive Thomas Ulmer to Board of Directors
01 November, 2020, Melbourne, Victoria - Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...
Oct 31, 2020
Aravax receives positive pre-IND feedback from FDA on PVX108 Phase 2 trial plans.
30 September 2019, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for...
Sep 29, 2019
Aravax Presents Additional Positive PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019
June 4, 2019, Melbourne, Victoria –Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and...
Jun 3, 2019